<H1>Chapter DOI: 10.1208/aapsj070249<br/>Cited-By Count: 13</H1><table border="1" width="30%"><tr><td>Total References</td><td>10</td></tr><tr><td>Springer references</td><td>2</td></tr><tr><td>Non Springer references</td><td>8</td></tr><tr><td>BibStructured Count</td><td width="10%">9</td></tr><tr><td>BibUnstructured Count</td><td width="10%">1</td></tr><tr><td>DOI already available in SpringerLink</td><td>5</td></tr><tr><td>Additional DOI extracted from CrossRef-Meta</td><td>1</td></tr><tr><td>Additional DOI extracted from CrossRef-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from ResearchGate-Web</td><td>0</td></tr><tr><td>Additional DOI extracted from SpringerLink-FUZZY-Search</td><td>0</td></tr><tr><td>Spelling Mistakes</td><td>NULL</td></tr><tr><td>Wrong DOI</td><td>0</td></tr><tr><td>ISBN</td><td>NULL</td></tr><tr><td>Web Link</td><td>NULL</td></tr><tr><td>DOI Obtained For Springer Published</td><td>0</td></tr><tr><td>DOI Obtained For Non Springer</td><td>1</td></tr><tr><td>DOI Obtained From Structured Ref</td><td>1</td></tr><tr><td>DOI Obtained From Unstructured Ref</td><td>0</td></tr><tr><td>Valid DOI Enriched</td><td>1</td></tr></table></br></br><table border="1">
<tr><th>Bib. ID</th><th>Ref. Type</th><th>References</th><th>DOI</th><th>Suspected DOI</th><th>DOI Source</th><th>Validated Elements</th><th>Validation Source</th></tr><tr><td>CR1</td><td>BibArticle</td><td>Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1984;9:545&#8211;554.</td><td><a href=http://dx.doi.org/10.2165/00003088-198409060-00004>10.2165/00003088-198409060-00004</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR2</td><td>BibBook</td><td>Beal SL, Sheiner LB, eds.<Emphasis Type="Italic">NONMEM Users Guides</Emphasis>. San Francisco: University of California at San Francisco; 1998.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR3</td><td>BibBook</td><td>U. S. Department of Health and Human Services.<Emphasis Type="Italic">Challenge and Opportunity on the Critical Path to New Medical Products</Emphasis>. Washington, DC: Food and Drug Administration; 2004.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR4</td><td>BibArticle</td><td>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1997;61:275&#8211;291.</td><td><a href=http://dx.doi.org/10.1016/S0009-9236(97)90160-0>10.1016/S0009-9236(97)90160-0</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR5</td><td>BibUnstructured</td><td>Data on file. Congnigen Corporation, 395 Youngs Rd, <span style='background:#C0FFC0'>Buffalo, NY</span> <span style='background:#FFFF0F'>14221</span>.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR6</td><td>BibArticle</td><td>Antal EJ, Grasela TH Jr, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part IIO Prospective data collection versus retrospective data assembly.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1989;46:552&#8211;559.</td><td><a href=http://dx.doi.org/10.1038/clpt.1989.185>10.1038/clpt.1989.185</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR7</td><td>BibArticle</td><td>Schmith VD, Fiedler-Kelly J, Phillips L, Grasela TH Jr. Prospective use of population pharmacokinetics/ pharmacodynamics in the development of cisatracurium.<Emphasis Type="Italic">Pharm Res.</Emphasis> 1997;14:91&#8211;97.</td><td><a href=http://dx.doi.org/10.1023/A:1012015719694>10.1023/A:1012015719694</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr><tr><td>CR8</td><td>BibArticle</td><td>Grasela TH, Antal EJ, Fiedler-Kelly J, et al. An automated drug concentration screening and quality assurance program for clinical trials.<Emphasis Type="Italic">Drug Inf J.</Emphasis> 1999;33:273&#8211;279.</td><td><a href=http://dx.doi.org/10.1177/009286159903300131>10.1177/009286159903300131</a></td><td>&nbsp;</td><td><b>CrossRef-Meta</b></td>
<td>Author_FamilyName_1, ArticleTitle, VolumeID, Author_FamilyName_2, FirstPage, Year</td><td>CrossRef</td></tr><tr><td>CR9</td><td>BibBook</td><td>FDA. Guidance for Industry:<Emphasis Type="Italic">Population Pharmacokinetics</Emphasis>. Washington, DC: Food and Drug Administration; 1999.</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>CR10</td><td>BibArticle</td><td>Stewart JJ, Allison PN Johnson RS. Putting a price on biotechnology.<Emphasis Type="Italic">Nature Biotechnology</Emphasis>. 2001;19:813&#8211;817.</td><td><a href=http://dx.doi.org/10.1038/nbt0901-813>10.1038/nbt0901-813</a></td><td>&nbsp;</td><td><b>SpringerLink</b></td>
<td align=center>---</td><td align=center>---</td></tr></table>